Thursday, July 9, 2026

pharma · Advanced Solid Tumor · RNAZ

Transcode Therapeutics

Transcenta Therapeutics is a pharma organization headquartered in Princeton, USA. It trades on NYSE under ticker RNAZ. Primary therapeutic focus areas include Advanced Solid Tumor. NovaPharmaNews links 2 clinical program

Princeton, USA HQ
93 Employees
Public company Type
RNAZ · NYSE Ticker
Company details
Status
Public
HQ
Princeton, USA
Employees
93
Programs
2
Drugs
0
Patents
0
Clinical program

TTX-MC138

Phase 2 · small molecule · Advanced Solid Tumor

TTX-MC138 for Advanced Solid Tumor is a Phase 2 program (small_molecule) at Transcode Therapeutics with 1 ClinicalTrials.gov record(s).

← All Transcode Therapeutics projects Phase 2 small molecule active

Internal code TTX-MC138-002

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Transcode Therapeutics
Phase
Phase 2
Modality
small_molecule
Indication
Advanced Solid Tumor
Status
active
Trials
1

Clinical trials